4D Molecular Therapeutics FDMT Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -220.1%-15.6pp | -204.5%+191,778pp | -191,982.5%+475,672pp | -667,654.5%+216,372pp | -884,026.1%-376,348pp | |
| EBITDA margin | -214.6%-15.6pp | -199%+187,972pp | -188,170.8%+465,838pp | -654,009.1%+210,317pp | -864,326.1%-369,223pp | |
| Returns | ||||||
| Return on invested capital | -51.1%-10.3pp | -40.9%+22.0pp | -62.9%-6.4pp | -56.5%+1.6pp | -58.2%+23.6pp | |
| Efficiency | ||||||
| Asset turnover | 0.2×0.0× | 0.2×+0.2× | 0×0.0× | 0×— | 0×0.0× | |
| Liquidity | ||||||
| Current ratio | 9.3×-0.1× | 9.4×+1.0× | 8.4×-0.3× | 8.7×-3.6× | 12.4×-2.6× | |
| Quick ratio | 9.3×-0.1× | 9.4×+1.0× | 8.4×-0.3× | 8.7×-3.6× | 12.4×-2.6× | |
| Cash ratio | 1.7×+0.3× | 1.4×+0.1× | 1.3×-0.9× | 2.2×-2.7× | 5×-0.2× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0.1×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $6.64-24.0% | $8.73+32.8% | $6.57-12.6% | $7.53-10.7% | $8.43-11.0% | |
| Valuation | ||||||
| Market capitalization | $602.22M+215% | $428.51M+5.6% | $405.84M+119% | $185.3M+23.9% | $149.56M-41.9% | |
| Enterprise value | $550.27M+574% | $389.69M+2.7% | $379.55M+189% | $131.22M+229% | $39.88M-70.0% | |
| Price / sales | 6.8×-8,306× | 5×-3,377× | 3,382×-2,233× | 5,615.1×-887× | 6,502.5×-457× | |
| Price / book | 1.3×+0.9× | 0.8×-0.3× | 1.1×+0.7× | 0.4×+0.1× | 0.3×-0.2× | |
| EV / sales | 6.2×-3,544× | 4.6×-3,158× | 3,162.9×-813× | 3,976.3×+2,242× | 1,734.1×-1,854× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do 4D Molecular Therapeutics's ratios come from?
- Every ratio is computed from 4D Molecular Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
